-- Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-
Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event
On 6ix: 6ix.com/news/rhythm-pharmaceuticals-announces-updates-on-mc4r-pathway-programs-at-rd-event-2023-12
Watch Rhythm Pharmaceuticals' latest callRhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2026 Earnings Call · Replay · Nov 3Read the transcript of Rhythm Pharmaceuticals (NASDAQ:RYTM) Q3 2026 Earnings CallRhythm Pharmaceuticals, Inc. on 6ix
Earlier from Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update
- Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)
- Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023
- Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023
- Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®
Later from Rhythm Pharmaceuticals
- Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023
- Rhythm Pharmaceuticals and LG Chem Life Sciences Enter Agreement for Rhythm to Acquire Global Rights to Oral MC4R Agonist LB54640
- Rhythm Pharmaceuticals Announces Completion of Screening for Enrollment in Setmelanotide Phase 3 Hypothalamic Obesity Trial and Additional Updates
- Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 22, 2024
- Rhythm Pharmaceuticals Announces Positive Reimbursement Decision in Italy for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
Follow Rhythm Pharmaceuticals into a list and get an email when it puts out news.
Follow Rhythm Pharmaceuticals